Stock Taper 
CELG-RI
$0.12
▲ UP 0.08% (0.00)
KEY STATISTICS
Market Cap$244.92 M
52w High$0.12
52w Low$0.11
Dividend Yield67.52%
FrequencyAnnual
P/E—
Volume54.17K
Shares Out.2.04B
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Christopher S. Boerner
COMPENSATION 2026
Salary$1,687,115
Stock Awards$13,457,248
Incentive Plan Pay$4,201,602
All Other Comp.$804,937
Total$20,150,902
ABOUT
SECTOR
Healthcare
WENT PUBLIC
November 21, 2019
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
34,100
UPCOMING EARNINGS
DateOct 29, 2026
DayThursday
Rev. Est.$12.59B
OCT
29
THU
PRICE
$0.12 ▲ UP 0.08% (+$0.00)About Bristol-Myers Squibb Company Ce
http://www.bms.com ↗Bristol Myers Squibb is a Princeton-based biopharmaceutical company founded in 1933, specializing in small molecules, biologics, and CAR-T cell therapies across discovery, development, manufacturing, and sales.
INDUSTRY
Medical - Pharmaceuticals
A PRODUCT BRISTOL-MYERS SQUIBB COMPANY CE IS KNOWN FOR
Opdivo (nivolumab)
Opdivo, a top-selling cancer immunotherapy by Bristol-Myers Squibb with $10 billion in 2023 sales, treats cancers like melanoma, lung, and kidney, exemplifying their focus on innovative immune-based oncology treatments.
Revenue by Products
| Icon | PRODUCT | Q1-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
 | Eliquis | $3.56B | $10.88B ▲ | $4.14B ▼ | $4.48B ▲ |
 | Opdivo | $2.27B | $7.78B ▲ | $2.15B ▼ | $2.48B ▲ |
 | Orencia | $770M | $2.94B ▲ | $818M ▼ | $1.03B ▲ |
 | Yervoy | $624M | $2.28B ▲ | $651M ▼ | $769M ▲ |
 | Reblozyl | $478M | $1.85B ▲ | $555M ▼ | $735M ▲ |
 | Other Growth Brands | $403M | $1.52B ▲ | $581M ▼ | $653M ▲ |
 | Breyanzi | $263M | $1.09B ▲ | $411M ▼ | $484M ▲ |
 | Revlimid | $936M | $2.02B ▲ | $349M ▼ | $425M ▲ |
 | Camzyos | $159M | $909M ▲ | $314M ▼ | $416M ▲ |
 | Opdualag | $252M | $933M ▲ | $295M ▼ | $349M ▲ |
 | Abecma | $103M | $324M ▲ | — | — |
 | Opdivo Ovantig | $9M | $229M ▲ | $163M ▼ | $261M ▲ |
 | PomalystImnovid | $658M | $2.08B ▲ | $513M ▼ | $204M ▼ |
 | Other Legacy Brands | $199M | $599M ▲ | $156M ▼ | $170M ▲ |
 | Zeposia | $107M | $470M ▲ | $118M ▼ | $169M ▲ |
 | Sprycel | $175M | $318M ▲ | $73M ▼ | $88M ▲ |
 | Sotyktu | $55M | $236M ▲ | $69M ▼ | $87M ▲ |
 | Cobenfy | $27M | $128M ▲ | $56M ▼ | $63M ▲ |
 | Abraxane | $105M | $263M ▲ | $50M ▼ | $55M ▲ |
 | Krazati | $48M | $157M ▲ | $50M ▼ | $55M ▲ |
Revenue by Geography
| Map | REGION | Q1-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
 | UNITED STATES | $7.87B | $25.41B ▲ | $7.79B ▼ | $8.99B ▲ |
 | Rest Of World | $3.11B | — | — | — |
 | Other Region | $218M | $869M ▲ | $257M ▼ | $318M ▲ |
INSTITUTIONAL OWNERSHIP
SHARES OWNED
0.06%
HOLDERS
24
TOP 12 OF 24 · RANKED BY POSITION SIZE
Toronto Dominion Bank
Transcend Capital Advisors, LLC
Davenport & Co LLC
Bank Of America Corp /De/
Citadel Advisors LLC
Purkiss Capital Advisors LLC
Susquehanna International Group, Llp
Watts Gwilliam & Co., LLC
Fifth Third Bancorp
Two Sigma Securities, LLC
Virtu Financial LLC
Private Advisor Group, LLC
RATINGS SNAPSHOT
Overall rating: A+
Discounted Cash Flow5
Return On Equity5
Return On Assets5
Debt To Equity1
Price To Earnings3
Price To Book5
Overall Score4
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 AMGN | $430.19 | COMPARE |
 GILD | $146.43 | COMPARE |
 PFE | $28.55 | COMPARE |
 VRTX | $542.47 | COMPARE |
 CVS | $94.02 | COMPARE |
 MDT | $90.84 | COMPARE |
 SNY | $44.48 | COMPARE |
 MCK | $890.41 | COMPARE |